Skip to main content

Table 5 Rocket-AF study: primary ischemic outcomes

From: Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective

Outcomes

Rivaroxaban

Warfarin

P

NNT

Primary outcomes (noninferiority)a

1.71

2.16

<0.001

222

Primary outcomes (on treatment)

1.70

2.15

0.015

222

Non-central nervous system embolism

0.04

0.19

0.003

667

Vascular death, stroke, embolism

3.11

3.63

0.034

192

Ischemic stroke

1.34

1.42

0.581

1250

Unknown cause

0.06

0.10

0.366

2500

  1. NNT, number needed to treat. Data from Mahaffey KW. AHA Scientific Sessions 2010.
  2. aStroke and extracranial embolism, event rate per 100 patients/year.